Marine Toxins

Marine Toxins
Accession Number

Toxic or poisonous substances elaborated by marine flora or fauna. They include also specific, characterized poisons or toxins for which there is no more specific heading, like those from poisonous FISHES.

DrugDrug Description
Latrunculin ALatrunculin A is an actin binding macrolide purified from the red sea sponge Latrunculia magnifica. It is under investigation for the treatment of cancer. It disrupts actin polymerization, prevents mitotic...
Domoic AcidNot Available
TetrodotoxinFor the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence.
ZiconotideAn N-type calcium channel antagonist used to manage patients with severe chronic pain who cannot tolerate, or who have not responded adequately to other treatments such as intrathecal morphine and systemic analgesics.
Latrunculin BLatrunculin B is a 14-membered macrolide attached to 2-thiazolidinone moiety, isolated from Red Sea sponge Latrunculia magnifica.
NeosaxitoxinNeosaxitoxin is under investigation in clinical trial NCT01786655 (Safety Study of Long-Acting Local Anesthetic).
alpha-Conotoxin VC 1.1Investigated for use/treatment in pain (acute or chronic).
Drugs & Drug Targets
Latrunculin AActin, alpha skeletal muscletarget
Latrunculin AGelsolintarget
Latrunculin AIota toxin component Iatarget
Domoic AcidGlutamate receptor ionotropic, kainate 2target
TetrodotoxinSodium channel protein type 1 subunit alphatarget
TetrodotoxinSodium channel protein type 2 subunit alphatarget
TetrodotoxinSodium channel protein type 3 subunit alphatarget
TetrodotoxinSodium channel protein type 8 subunit alphatarget
ZiconotideVoltage-dependent N-type calcium channel subunit alpha-1Btarget
ZiconotideVoltage-dependent P/Q-type calcium channel subunit alpha-1Atarget
Latrunculin BActin, alpha skeletal muscletarget
Latrunculin BMKL/myocardin-like protein 1target
Latrunculin BProtein spire homolog 2target